Backbone-Minimised Nanoplasmid DNA Systems Enable High-Titre AAV Production in Suspension HEK293 Platforms
Pharmaceutics · 30.06.2026 · 18 (7) · 814
DOI: 10.3390/pharmaceutics18070814 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 30.06.2026. Verfasst von Lewis Hall und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemical Engineering, University College London, London WC1E 6BT, UK. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Scalability and cost remain major manufacturing barriers limiting broad patient access to adeno-associated virus (AAV) gene therapies. While capsid engineering has advanced vector biology, comparatively fewer innovations have addressed fundamental upstream productivity constraints. Transient triple-plasmid transfection is still the dominant AAV production platform and relies on large bacterial backbone plasmids that impose DNA burden and contribute significantly to the cost-of-goods.
Methods
In this study, we evaluated a compact NanoplasmidTM DNA system (Aldevron) as a structural redesign of the transfection substrate to enhance upstream productivity. Conventional pUC-based triple-plasmid systems were compared to fully substituted NanoplasmidTM equivalents across suspension HEK293 production platforms optimised via response surface Design of Experiments. Hybrid plasmid configurations were also constructed to assess component-level contributions.
Results
Complete substitution with NanoplasmidTM resulted in up to a 10-fold increase in vector genome titre relative to conventional plasmids under matched conditions. Hybrid systems failed to recapitulate this improvement, demonstrating that full-system backbone minimisation is required to ensure high yield. Productivity gains were preserved across transfection reagents and suspension media. NanoplasmidTM deployment represents a scalable, capsid-independent upstream intensification approach that improves yield without altering capsid biology.
Conclusions
Integration of this approach within a design-for-manufacturability framework offers a practical route to reducing bacterial plasmid elements increasing safety, enhancing process robustness, and improving economic feasibility of AAV therapeutics.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Biochemical Engineering, University College London, London WC1E 6BT, UK.
- School of Pharmacy, University College London, London WC1N 1AX, UK.
- Biotherapeutics and Advanced Therapies, Science and Research Group, Medicines and Healthcare Products Regulatory Agency, Potters Bar EN6 3GQ, UK.
ORCID-Profile: Lewis Hall, Michael J Fiore, Ahad A Rahim, Giulia Massaro
Zitieren
APA
Hall, L., Fiore, M. J., Abramovich, J., Kerridge, C., Rahim, A. A., Rafiq, Q. A., & Massaro, G. (2026). Backbone-Minimised Nanoplasmid DNA Systems Enable High-Titre AAV Production in Suspension HEK293 Platforms. Pharmaceutics, 18(7), 814. https://doi.org/10.3390/pharmaceutics18070814
Vancouver
Hall L, Fiore MJ, Abramovich J, Kerridge C, Rahim AA, Rafiq QA, et al. Backbone-Minimised Nanoplasmid DNA Systems Enable High-Titre AAV Production in Suspension HEK293 Platforms. Pharmaceutics. 2026;18(7):814. doi:10.3390/pharmaceutics18070814
BibTeX
@article{Hall2026,
author = {Hall, Lewis and Fiore, Michael J and Abramovich, Joel and Kerridge, Claire and Rahim, Ahad A and Rafiq, Qasim A and Massaro, Giulia},
title = {Backbone-Minimised Nanoplasmid DNA Systems Enable High-Titre AAV Production in Suspension HEK293 Platforms},
journal = {Pharmaceutics},
year = {2026},
volume = {18},
number = {7},
pages = {814},
doi = {10.3390/pharmaceutics18070814}
}
EUVIMED